Therefore, with this study, aiming to explore the risk factors for neutropenia after CRT for EC, screening for more effective and cost-efficient prophylactic application of G-CSF in high-risk populations, more precise and rational prevention of neutropenia during CRT in patients with EC, thereby reducing patient hospitalization rates, lowering patient treatment costs, and increasing patient survival. This evidence concerns the gene CSF3 and Decreased total neutrophil count.